image: Targeting Microbiota 2025 will be held on November 5-6 at The Westin Hotel Valencia, Spain
Credit: International Society of Microbiota
The 12th World Congress on Targeting Microbiota, organized by the International Society of Microbiota (ISM), will convene in Valencia, Spain, on November 5-6, 2025, to explore how microbiota research is reshaping human health, from fundamental mechanisms to clinical translation.
“Microbiome science is no longer an observational field, it is becoming the foundation of a new medical paradigm”, says Marvin Edeas, Chairman of the scientific committee of ISM. “Understanding how microbial metabolites and host signals interact allows us to predict and modulate disease trajectories. This is the beginning of dynamic medicine”.
From Mechanisms to Medicine: Unraveling Microbial Communication
The microbiota is now recognized as a dynamic organ, producing molecules such as butyrate, indoles, and bile acids that regulate gene expression, immunity, and mitochondrial function.
Microbiota as a Diagnostic and Therapeutic Axis
New data reveal how microbiota signatures can serve as biomarkers of inflammation, metabolism, and aging, while microbial metabolites become therapeutic effectors.
These insights establish the microbiota as a pillar of predictive, preventive, and personalized medicine (3P medicine).
Key benefits include:
• Optimizing energy metabolism and mitochondrial resilience
• Modulating neuro-immune function
• Restoring metabolic and immune homeostasis
From Discovery to Translation
Day 2 highlights technologies enabling clinical impact:
• Standardized metagenomic pipelines for human trials
• Quantitative metaproteomics for microbial function mapping
• AI-driven analytics and organ-on-chip systems for precision interventions
• Microbiota-based therapeutics for inflammatory and skin diseases
These innovations demonstrate the convergence of biotechnology, computation, and clinical medicine, turning microbiome research into actionable healthcare tools.
Journal Collaboration: Microbiome and Host (Bioscientifica Publishing)
The ISM is proud to collaborate with Microbiome and Host, an open-access journal advancing knowledge on microbiome–host interactions in health and disease.
This partnership strengthens ISM’s commitment to scientific excellence, open access, and translational medicine.
Selected highlights from the congress will be featured in Microbiome and Host, expanding the reach of microbiome-driven discoveries.
Olobion and Microomics Systems S.L., are the major supporters of ISM 2025.
A Global Scientific and Industrial Convergence
The 2025 agenda includes 105 communications and 213 participants from 23 countries, reflecting unprecedented academic and industrial engagement.
Attending organizations include:
Olobion, Microomics Systems S.L., ADM, Affidea, AINIA, Cantabria Labs, Clasado Limited, Copan Italia SpA, Cultech Limited, KOLMAR Korea, Meiji Seika Pharma, Medipredict, NAOS ILS, Naturlifes Group Inc, Nutribiótica SL, SILAB, Seventure Partners, and others.
Their participation underscores how microbiome science, biotechnology, and clinical innovation are merging to define the next era of medicine.
About the International Society of Microbiota (ISM)
The ISM fosters collaboration between academia, hospitals, and industry to accelerate the translation of microbiome research into precision diagnostics, personalized nutrition, and microbiota-based therapies.
For more information: www.microbiota-site.com